Issue 69

Patenting psychedelic medicines

Patenting medications provides manufacturers with a period of market exclusivity, to incentivise drug development by enabling the company to monopolise sales.

In the UK and North America, new drugs are patented upon discovery, rather than regulation, with a patent term of 20 years.

MDMA was first patented in 1914, LSD in 1957 and psilocybin in 1963, so the patents governing their use have long since expired.

As a result, companies are creating novel psychedelic compounds and formulations, based on classic tryptamines, which can be patented, and are regulating these through clinical trials.

RESEARCH CONDUCTED ON PSILOCYBIN THERAPY'S DURABILITY

A study from Johns Hopkins found psilocybin-assisted therapy alleviates symptoms of depression for 12 months.

CAN PSILOCYBIN BECOME A LEGITIMATE MENTAL HEALTH TREATMENT?

As mainstream acceptance of psychedelic healthcare grows, ITV explored psilocybin’s medical utility.

BUSINESS AND INVESTMENT

Small Pharma shares data from DMT study.

FDA raises concerns over ketamine nasal spray.

Seattle’s psychedelic revolution has arrived.

Universal Ibogaine and Osoyoos Indian Band enter MOU for detox clinic.

Awakn files patent for novel empathogen.

PharmaTher secures patent for ketamine formulation.

PSYCH Symposium: London 2022

PSYCH Symposium enables industry leaders to connect and collaborate to expedite access to psychedelic healthcare across Europe.

The conference will bring together leading figures from policy, science and business.

Speakers include:

Rick Doblin – Founder, MAPS
Christian Angermayer – Founder, atai Life Sciences
Cosmo Feilding Mellen – CEO, Beckley Psytech

Secure your ticket today to connect with industry influencers, learn from the sector’s thought leaders and contribute to the future of psychedelics as medicine in Europe.

For speaking and partnership opportunities, please visit the website.

Ticket registration

- Rick Doblin, Founder of MAPS

Symposium website

SCIENCE AND RESEARCH

Study of LSD microdosing shows no therapeutic effect.

Can psychedelics help make dying easier?

Enveric and University of Calgary partner on psilocybin analogue studies.

At Harvard, psychedelic drugs’ tentative renaissance.

REGULATION AND LEGISLATION

Bill in Oklahoma is approved to decriminalise psilocybin possession.

DEA’s administrative court to rule on prohibition of tryptamines.

Oregon bill on psilocybin equity passes in committee hearing.